In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Abaloparatide (Tymlos) | Natural fragment Teriparatide (PTH 1-34) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 878 | 2,709 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 84 (70 in people) | 209 (168 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 21 · 5 active4 more mention it but do not test it | 168 · 15 active30 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Tymlos says: “A synthetic PTH-related peptide analog approved for osteoporosis in selected patients”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Abaloparatide (Tymlos) | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletal | 724290395354 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Forteo says: “The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients”
2,2281286913263
| Adverse eventsWhole body | 43412 | 16313726 |
|---|
| PainMusculoskeletal | 55 | 6262 |
|---|
| Receptor activity and mechanismReproductive and sexual health | 43241 | 46151516 |
|---|
| PharmacokineticsPharmacology | 44 | 30273 |
|---|
| Kidney functionKidney and urinary | 22 | 27243 |
|---|
| Exercise and physical functionMusculoskeletal | 44 | 1818 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 11 | 1212 |
|---|
| Treatment adherence and retentionWhole body | 55 | 66 |
|---|
| Cardiovascular eventsCardiovascular | 55 | 734 |
|---|
| Heart functionCardiovascular | 541 | 211 |
|---|
| Tendon and ligament healingMusculoskeletal | 99 | 99 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Abaloparatide (Tymlos) | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | 8.48% BMD percentage change Placebo: 1.17% Dose studied: 80 μg daily12 monthsn = 2282022 | 7.2% Lumbar spine BMD change Dose studied: 20 microg once daily18 monthsn = 4282007 |
8.48%
BMD percentage change
Placebo: 1.17%
Dose studied: 80 μg daily12 monthsn = 2282022
7.2%
Lumbar spine BMD change
Dose studied: 20 microg once daily18 monthsn = 4282007
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Abaloparatide (Tymlos) | Teriparatide (PTH 1-34) |
|---|---|---|
| PainMusculoskeletalCompared as: difference from placebo, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −31% Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size. |
| Exercise and physical functionMusculoskeletalCompared as: value in the arm that got the peptide, in s | No comparable result 2 randomized-trial results measure it in another way or another unit. | −3.2 to −5.9 s TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks Dose studied: 20 μg every day78 weeksn = 1712017 |
|---|
| Adverse eventsNervous system and cognitionCompared as: value in the arm that got the peptide, in % | No comparable result 15 randomized-trial results measure it in another way or another unit. | 10% Nasopharyngitis Dose studied: 20 μg once daily12 monthsn = 4322017 |
|---|
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in bpm | 7.9 bpm Heart rate change · abaloparatide at 1 hour Placebo at 1 hour: 1.2 bpm n not reported2020 | No comparable result 1 randomized-trial result measure it in another way or another unit. |
|---|
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 13% Nausea rate Dose studied: 20 g/day as printed6 monthsn = 1042006 |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
−31%
Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size.
Dose studied: 20 microgmedian 19 monthsn = 1,0852005
No comparable result
2 randomized-trial results measure it in another way or another unit.
−3.2 to −5.9 s
TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks
Dose studied: 20 μg every day78 weeksn = 1712017
No comparable result
15 randomized-trial results measure it in another way or another unit.
10%
Nasopharyngitis
Dose studied: 20 μg once daily12 monthsn = 4322017
7.9 bpm
Heart rate change · abaloparatide at 1 hour
Placebo at 1 hour: 1.2 bpm
n not reported2020
No comparable result
1 randomized-trial result measure it in another way or another unit.
No randomized trial result
1 result from other study designs.
13%
Nausea rate
Dose studied: 20 g/day as printed6 monthsn = 1042006
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 21 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Radius Health, Inc.511 participants5 Aug 2019 to 9 Nov 2021
Postmenopausal Osteoporosis
Radius Health, Inc.228 participants3 May 2018 to 8 Sept 2021
Osteoporosis · Osteoporosis, Age-Related · Osteoporosis Localized to Spine · Age Related Osteoporosis · Osteoporosis Senile · Osteoporosis of Vertebrae
4 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 168 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Eli Lilly and Company1,366 participantsOct 2012 to Jul 2016
Postmenopausal Osteoporosis
Eli Lilly and Company712 participantsJun 2006 to Jun 2010
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
30 more mention it but do not test it. They only measure it or name it in their text.